



EUROPEAN
HEMATOLOGY
ASSOCIATION

EHA25 VIRTUAL

25th Congress of the European Hematology Association

VIRTUAL EDITION



EUROPEAN
HEMATOLOGY
ASSOCIATION

EHA25 VIRTUAL

Abstract S143: Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib, with the BCL2-inhibitor venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Courtney DiNardo, MD MSCE

Department of Leukemia

MD Anderson Cancer Center

Houston TX, USA




Disclosure Slide

Research Support (to institution):

- Abbvie, Agios, Calithera, Celgene, Daiichi-Sankyo

Consultant/Advisory Board:

- Abbvie, Agios, Celgene, Daiichi-Sankyo, Jazz, ImmuneOnc, Novartis, Notable Labs



IDH1 Mutations in AML


- Occur in 6-14% of AML
- Enriched older patients, often with intermediate cyto
 - ~10% of AML from MDS; ~20% of AML from MPNs
- Increased dependency on BCL-2 and lower apoptotic threshold via cytochrome C oxidase inhibition
- Ivosidenib monotherapy:
 - Treatment Naïve (TN) AML CR/CR_h : 42%
 - Relapsed/Refractory (R/R) AML CR/CR_h : 30%
- Azacitidine + ivosidenib for TN AML CR/CR_h : 69%
- Azacitidine + venetoclax for TN IDH1/2 AML CR/CR_h : 71%

Key Study Objectives

- Determine safety and tolerability of IVO+VEN \pm AZA
- Determine MTD and RP2D
- Determine overall response rate (ORR): CR + CR_i + CR_h + MLFS + PR
- Determine time to event endpoints
- Evaluation of MRD by flow cytometry

Study Design

Phase 1b: Dose Escalation



Phase 1 Cohorts	Venetoclax	Ivosidenib	Azacitidine
Cohort #4 (n=TBD)	800mg once daily	500mg once daily	75 mg/m ² days 1-7
Cohort #3 (n=8)*	400mg once daily	500mg once daily	75 mg/m ² days 1-7
Cohort #2 (n=6)	800mg once daily	500mg once daily	
Cohort #1 (n=7) [†]	400mg once daily	500mg once daily	

Complete! {

Future Phase 2: Confirm efficacy in 2 cohorts (n=20 each) of treatment-naïve and R/R IDH1-mutated patients



*additional 6 patients being enrolled due to 1 DLT of TLS

[†] One enrolled patient was invaluable and was replaced

Venetoclax PK and PD Results

VEN+IVO oral doublet combination

- 53% decrease in mean VEN steady state AUC
- 47% decrease in C_{max}



Key Inclusion Criteria

- Age \geq 18
- ECOG \leq 2
- *IDH1* R132 mutation
- Advanced Myeloid Malignancy
 - MDS (EB-1/EB-2)
 - AML (*de novo*/secondary)
 - R/R AML
- Adequate renal and liver function

Key Exclusion Criteria

- Prior ivosidenib
- Prior venetoclax
- CYP3A4 inhibitors/inducers in preceding 3 days*
- Active GVHD
- Severe GI / metabolic condition

*azoles and strong/moderate CYP3A4 inhibitors were additionally excluded during cycle 1 and 2 for accurate PK/PD assessments



Patient Demographics	All Cohorts, N (%)	Cohort #1 IVO+VEN 400 (N=7)	Cohort #2 IVO+VEN 800 (N=6)	Cohort #3 IVO+VEN 400+AZA (N=8)
Median Age, years (range)	67	68 (37-84)	69 (44-79)	64 (57-75)
Sex, Male (N, %)	12 (57)	3 (43)	3 (50)	6 (75)
Disease Category				
MDS	4 (19)	1	1	2
De Novo AML	3 (14)	1	1	1
Secondary AML	2 (10)	-	1	1
Treated Secondary AML	3 (14)	-	1	2
Relapsed/Refractory AML	9 (43)	5	2	2
ELN Risk Group				
Favorable	7 (33)	2	3	2
Intermediate	3 (14)	2	1	-
Adverse	11 (52)	3	2	6

Adverse Event N(%)	Grade 1/2	Grade 3/4
Pneumonia	-	14 (70)
Febrile neutropenia*	-	10 (50)
IDH Differentiation syndrome	3 (15)	1 (5)
Abdominal pain	-	3 (15)
Tumor lysis syndrome	1 (5)	1 (5)
Acute kidney injury	-	2 (10)
Leukocytosis	-	2 (10)
Thrombocytopenia	-	2 (10)
Sepsis	-	2 (10)
Diarrhea	15 (75)	-
Nausea	6 (30)	-
Vomiting	5 (25)	-

- No 30-day or 60-day mortality
- *1 death on study due to febrile neutropenia in setting of persistent disease
- AE's of special interest: IDH differentiation syndrome (N=4), TLS (N=2)
- Dose limiting toxicities: 1 tumor lysis syndrome (occurring in patient with solitary kidney)

Overall Response N (%)	All Cohorts N (%)	Cohort #1 IVO+VEN 400 (N=6)‡	Cohort #2 IVO+VEN 800 (N=6)	Cohort #3 IVO+VEN+AZA (N=8)
ORR, N(%)	18 (90)	4 (67)	6 (100)	8 (100)
Composite CR*	16 (80)	4 (67)	6 (100)	6 (75)
CR	8 (40)	3 (50)	3 (50)	2 (25)
CR _h	2 (10)	-	2 (33)	-
CR _i	6 (30)	1 (17)	1 (17)	4 (50)
MLFS	1 (5)	-	-	1 (13)
HI	1 (5)	-	-	1 (13)
NR	2 (10)	2 (33)	-	-
Flow MRD Negative [†]	8 (50)	2 (50)	2 (33)	4 (67)

* CR_h and CR_i represented as mutually exclusive

† Among patients achieving a composite CR

‡ One patient in cohort 1 was inevaluable and replaced


Response by Disease Subgroup

Response, N (%)	De Novo AML (N=3)	sAML/ts-AML (N=5)	R/R AML (N=8)	MDS (N=4)
Overall Response Rate N(%)	3 (100)	5 (100)	6 (75)	4 (100)
Composite CR (CRc)*	3 (100)	4 (80)	5 (63)	4 (100)
CR	2 (66)	2 (40)	1 (13)	3 (75)
CR_h	-	-	2 (25)	
CR_i	1 (33)	2 (40)	2 (25)	1 (25)
MLFS	-	-	1 (13)	-
HI	-	1 (20)	-	-
NR	-	-	2 (25)	-
Flow MRD negative[†]	1 (33)	2 (50)	3 (60)	2 (50)




* CR_h and CR_i mutually exclusive

† Among patients achieving a Composite CR


Months: 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25



Hematologic Response




Median Cycle Lengths




* 7 of 8 patients in cohort 3 had received prior therapy; including 2 with relapsed MDS, and 3 with secondary AML from MDS

Overall Survival




Event Free Survival




Median Follow up: 7 months


Survival Outcomes by Key Subgroups

Overall Survival by Study Cohort



Overall Survival by Disease





Molecular Profiling

- Diverse molecular landscape seen across patients
- Active signaling mutations in 66% of patients without response or with relapse
- Molecular subgroups as defined by TCGA AML (NEJM, 2013)


Active Signaling Mutations Associated with Treatment Resistance

Outcomes

Response, N (%)	Active Signaling (N=8)	No signaling (N=12)
Overall Response Rate, N(%)	7 (88)	11 (92)
Composite CR	6 (75)	10 (83)
CR	1 (13)	6 (50)
CR _h	1 (13)	2 (17)
CR _i	4 (50)	2 (17)
MLFS	-	1 (8)
PR	1 (13)	-
NR	1 (13)	1 (8)
MRD Negative	2 (33)	6 (60)
Median DOR, Mo. (95% CI)	1.6 (0.3-3)	11.9 (NE)*

*p-value: 0.043

Overall Survival




Active Signaling mutations: *NRAS*, *KRAS*, *FLT3-ITD/TKD*, *PTPN11*, *NF1*

Undetectable Flow MRD at CR Associated with Superior Survival

Demographics	All CR	MRD neg. (N=8)	MRD Pos/Indeter (N=8)
Cohort #1, N (%)	4	2 (50)	2 (50)
Cohort #2, N (%)	6	2 (33)	4 (67)
Cohort #3, N (%)	6	4 (67)	2 (33)
<i>Disease subgroup</i>			
MDS	4	2 (50)	2 (50)
De Novo AML	3	1 (33)	2 (67)
sAML/ts-AML	4	2 (50)	2 (50)
R/R (AML/MDS)	5	3 (60)	2 (40)
Progressive disease	6	-	6 (100)
Median DOR, Mo. (95% CI)	5.7 (1-23)	NR*	3.0 (1.5-4.6)

*Median follow up: 2.5 Months



Conclusions

- IVO+VEN ± AZA is an effective and molecularly targeted regimen for advanced *IDH1* mutated myeloid malignancies
- IVO+VEN ± AZA is well tolerated
 - Common grade 3/4 adverse events: pneumonia, febrile neutropenia
 - Longer treatment cycles required with the AZA + IVO + VEN triplet for cytopenias
- IVO+VEN ± AZA therapy is effective:
 - Composite complete response in 80% of patients
 - Undetectable MRD by flow in 50% of pts with CR, responses ongoing
- **Recommended phase II dose and efficacy data forthcoming**



EUROPEAN
HEMATOLOGY
ASSOCIATION

EHA25 VIRTUAL

Thank you!



cdinardo@mdanderson.org